CAPECITABINE (BDOCIN) 500MG Tablet

$124.00

Capecitabine BDOCIN 500mg Tablet represents a cornerstone in the management of various cancers, offering a targeted and effective therapeutic option to improve patient outcomes. By selectively targeting cancer cells while minimizing systemic toxicity, Capecitabine plays a crucial role in slowing disease progression and prolonging survival in individuals affected by colorectal cancer,

Tag:

CAPECITABINE BDOCIN

Description

Capecitabine (BDOCIN) Tablet 500mg is an oral chemotherapy medication used in the treatment of various types of cancer, including breast cancer, colorectal cancer, and gastric cancer. It contains capecitabine as its active ingredient, which is a prodrug that is converted into 5-fluorouracil (5-FU) in the body. 5-FU is a cytotoxic agent that interferes with DNA synthesis and cell division, leading to the death of rapidly dividing cancer cells.

Key Features:

Prodrug of 5-Fluorouracil: Capecitabine is converted into 5-fluorouracil (5-FU) in the body by enzymes present in tumor tissue. 5-FU is a potent cytotoxic agent that disrupts DNA synthesis and inhibits cell division, ultimately leading to the death of cancer cells.
Treatment of Various Cancers: Capecitabine (BDOCIN) Tablet 500mg is indicated for the treatment of various types of cancer, including metastatic breast cancer, colorectal cancer, and gastric cancer. It may be used alone or in combination with other chemotherapy agents or targeted therapies, depending on the specific type and stage of cancer.
Oral Administration: Capecitabine (BDOCIN) Tablet 500mg is administered orally, typically twice daily, with water and within 30 minutes after a meal. The convenient dosing regimen enhances patient compliance and adherence to treatment.
Dose Flexibility: Capecitabine (BDOCIN) Tablet 500mg is available in a fixed dosage strength of 500mg, allowing for easy and accurate dosing. However, the actual dose prescribed may vary depending on factors such as the patient’s body surface area and overall health status.
Efficacy: Clinical studies have demonstrated the efficacy of capecitabine in prolonging progression-free survival and overall survival in patients with metastatic breast cancer, colorectal cancer, and gastric cancer. It has shown comparable efficacy to intravenous 5-fluorouracil (5-FU) with a more favorable side effect profile.
Safety Profile: Capecitabine generally has a manageable safety profile when used as directed. However, like all chemotherapy medications, it may be associated with certain side effects, including hand-foot syndrome, diarrhea, nausea, vomiting, and myelosuppression. Patients should be closely monitored for adverse reactions during treatment.
Patient Education: Patients prescribed Capecitabine (BDOCIN) Tablet 500mg should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
Consultation with Healthcare Provider: Treatment with Capecitabine (BDOCIN) Tablet 500mg should be initiated and monitored by a qualified oncologist or healthcare provider experienced in the management of cancer. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
Access and Affordability: Efforts should be made to ensure equitable access to Capecitabine (BDOCIN) Tablet 500mg for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to effective chemotherapy medications is crucial for improving patient outcomes and quality of life for those with cancer.